The CRL cites deficiencies in the Drug Master File pertaining to one
of the active pharmaceutical ingredients and in manufacturing
facilities, the company said in a regulatory filing.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-pharma-says-usfda-has-issued-crl-for-ryaltris/articleshow/69903560.cms
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment